BAY-60-7550 is a potent Type 2 cyclic nucleotide phosphodiesterases (PDE2) inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human). BAY-60-7550 is an analog of EHNA, which is more than 100-fold more potent and is highly selective for PDE2A.

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

BAY 607550

10 mM in DMSO

Phosphodiesterase (PDE)

Bay 60-7550 (1 μM) increases cGMP in the neuronal cultures compared with control . Compared with untreated control cells, proliferation of PASMCs from IPAH patients is significantly reduced by BAY 60-7550 (1 μM).

The PDE2 inhibitors Bay 60-7550 (1 mg/kg) reverses restraint stress-induced alterations in behavior, resulting in increased percentages of open-arm entries and open-arm time compared with the vehicle + restraint stress condition. In nonstressed mice, Bay 60-7550 produces a dose-dependent increase in percentages of open-arm entries and open-arm time compared with the vehicle-treated group; significant increases are observed at a dose of 3 mg/kg. In nonstressed mice, Bay 60-7550 increases, in a dose-dependent manner, the number of head-dips and time spent head-dipping, compared with vehicle-treated mice; significant increases are observed at doses of 1 and 3 mg/kg.

Inhibition of phosphodiesterase 2 augments cGMP and cAMP signaling to ameliorate pulmonary hypertension.
Bubb KJ,et al. Circulation. 2014 Aug 5;130(6):496-507. PMID:

分子结构图